/
/
Legend Biotech and Janssen Partner on CAR T Cell Treatment for Multiple Myeloma
Legend Biotech and Janssen Partner on CAR T Cell Treatment for Multiple Myeloma image
Legend Biotech and Janssen Partner on CAR T Cell Treatment for Multiple Myeloma
Posted May 31, 2018

Janssen Pharmaceuticals (Johnson & Johnson) and Legend Biotech (GenScript Biotech Corporation) have announced the initiation of a clinical trial for patients with relapsed or refractory myeloma using Chimeric Antigen Receptor T cell (CAR-T) therapy.

"This is a very exciting moment, as we celebrate the achievement of this critical milestone with our strategic partner Janssen," said Dr. Frank Zhang, Chairman and Chief Executive Officer of GenScript Biotech Corporation.  "We are very pleased with the pace of progress already achieved through the diligent efforts of the Janssen and Legend teams, reflecting our goal of bringing this important therapeutic option to patients as soon as possible."

This specific trial will test will target “B cell Maturation Antigen (BCMA), a molecule expressed on the surface of mature B lymphocytes and malignant plasma cells.”

"This milestone demonstrates tremendous progress, achieved within six months of establishing our development partnership with Janssen, and reflects the productive and collaborative relationship formed between the teams at both organizations that are working to bring this program forward swiftly," said Dr. Yuan Xu, Chief Executive Officer of Legend Biotech.

For the public statement made on May 30, read here or here.

The author Erika Johnson

about the author
Erika Johnson

Myeloma Crowd Editorial Contributor, Nursing student, and cancer advocate.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811